title: Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
abstract: Abacavir/lamivudine (ABC/3TC) is a nucleoside reverse transcriptase inhibitor used for treating human immunodeficiency viral (HIV) infections. Hypersensitivity reactions such as skin eruptions caused by ABC are well-known, but rarely occur in Asians. Raltegravir (RAL) is an integrase strand transfer inhibitor, that is now increasingly, used for treating HIV infections because it has few adverse effects. This retrospective analysis assessed the efficacy and safety of combined ABC/3TC and RAL in both treatment-naïve and -experienced Japanese patients with HIV infections. In all 11 treatment-naïve patients (100%), virological suppression to undetectable level was achieved. Liver transaminases, renal function, and serum lipid profiles showed no exacerbations up to 48 weeks of treatment. In 12 patients who were switched from previous regimens to ABC/3TC and RAL, HIV viral load was undetectable in 11 patients (91.6%), but remained detectable in 1 patient with poor adherence. Major reasons for switching regimens to ABC/3TC and RAL were hyperlipidemia and nausea. After switching, these adverse effects improved, and no new adverse effects were observed. Despite the small number of participants in this study, the results support the combination of ABC/3TC and RAL as a possible treatment choice in Japanese individuals with HIV-infection.
authors.affiliation: Department of General Medicine, Juntendo University School of Medicine.
authors.forename: Akihito
authors.initials: A
authors.lastname: Suzuki
authors.forename: Yuki
authors.initials: Y
authors.lastname: Uehara
authors.forename: Mizue
authors.initials: M
authors.lastname: Saita
authors.forename: Akihiro
authors.initials: A
authors.lastname: Inui
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Isonuma
authors.forename: Toshio
authors.initials: T
authors.lastname: Naito
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D044466:Asian People; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use*; D004338:Drug Combinations; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000453:epidemiology; D007677:Kidney Function Tests; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000453:epidemiology; D010865:Pilot Projects; D000068898:Raltegravir Potassium / Q000009:adverse effects* / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D008055:Lipids; D000068898:Raltegravir Potassium; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir